Sai Parenterals Ltd Financial Report

Company Overview

Sai Parenterals Ltd is a pharmaceutical company that engages in the development, manufacturing, and distribution of generic medicines, as well as providing Contract Development and Manufacturing Organization (CDMO) services to other pharmaceutical companies. The company's product portfolio includes a wide range of medicines for various therapeutic areas, including mental health, diabetes, breathing problems, infections, stomach issues, vitamins, pain relief, and skin care. These products are available in various forms, including injections, tablets, capsules, syrups, ointments, and advanced injectable formats like vials and pre-filled syringes.

Global Expansion

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

Sai Parenterals Ltd has expanded its global presence through strategic acquisitions, including the purchase of a 74.6% stake in Noumed, an Australian company that sells over-the-counter (OTC) products. The company has also established a presence in international markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa, where it began exporting medicines in 2023.

Valuation and Outlook

Sai Parenterals Ltd is valued at approximately 10.6x to price/sales on FY25 sales, which is considered fair in relation to its competitors. The company's consistent track record and superior financial metrics have contributed to its valuation, which is deemed fully priced. However, the company's long-term growth prospects and expanding global presence warrant a "Subscribe-Long Term" rating.